Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492387 | 0.91 | PPARG (0.46) | PPARGALOX5APTP53 | |
| SCHEMBL6492258 | 0.89 | ALDH1A1 (0.35) | PPARGSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL6488086 | 0.82 | ALOX5AP (0.42) | PPARGSMN1; SMN2MAPTALOX5APUSP2 | |
| SCHEMBL6500385 | 0.82 | PPARG (0.45) | PPARGSMN1; SMN2MAPTALOX5APUSP2 | |
| SCHEMBL6495279 | 0.81 | MAPT (0.36) | SMN1; SMN2MAPTALOX5APUSP2ALDH1A1 | |
| SCHEMBL6501064 | 0.79 | PIK3C2B (0.38) | PPARG | |
| SCHEMBL6488725 | 0.79 | ALOX5AP (0.37) | PPARGSMN1; SMN2MAPTALOX5APUSP2 | |
| SCHEMBL6492991 | 0.74 | DCTPP1 (0.36) | SMN1; SMN2MAPTUSP2HTTTHRB | |
| SCHEMBL6492244 | 0.74 | PPARG (0.46) | PPARGALOX5AP | |
| SCHEMBL6487607 | 0.74 | REN (0.38) | PPARGALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885SMN1; SMN2 1128/4885MAPT 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.